Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 17/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.49 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL319346 | 0.88 | KDM4E (0.52) | CTSAKDM4EALOX15TSHRACMSD | |
| SCHEMBL2554464 | 0.85 | SCN9A (0.59) | CTSAHSD17B14 | |
| SCHEMBL13758107 | 0.83 | KDM4E (0.53) | CTSAKDM4EALOX15TSHRACMSD | |
| SCHEMBL318982 | 0.82 | KDM4E (0.57) | CTSAKDM4EALOX15TSHRACMSD | |
| SCHEMBL11907284 | 0.82 | KMO (0.60) | CTSAKDM4EALOX15TSHRACMSD | |
| SCHEMBL28554483 | 0.82 | CTSA (0.53) | CTSAKDM4EALOX15TSHRACMSD | |
| SCHEMBL5670738 | 0.81 | KDM4E (0.47) | CTSAKDM4EALOX15TSHRACMSD | |
| SCHEMBL5174856 | 0.81 | KDM4E (0.55) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL27906998 | 0.80 | ATR (0.45) | CTSAALOX15 | |
| SCHEMBL16517079 | 0.80 | KDM4E (0.46) | CTSAKDM4EALOX15TSHRACMSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598175-B2 | Heteroarylamide pyrimidone derivatives | SANOFI (FR) | 2013-12-03 | — | — | US | claimed |
| EP-2162443-B1 | HETEROARYLAMIDE-SUBSTITUTED PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SANOFI SA (FR) | 2013-07-31 | — | — | EP | claimed |
| US-8198287-B2 | Substituted heteroaryl pyridopyrimidone derivatives | SANOFI-AVENTIS (FR) | 2012-06-12 | — | — | US | claimed |
| CN-101563328-B | substituted heteroaryl Pyridopyrimidinone derivatives | SANOFI AVENTIS | 2012-03-14 | — | — | CN | claimed |
| CN-101679306-B | Heteroaryl amide substituted pyrimidone derivatives for the treatment of neurodegenerative diseases | SANOFI-AVENTIS (FR) | 2011-12-28 | — | — | CN | claimed |
| US-20100081677-A1 | HETEROARYLAMIDE PYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2010-04-01 | — | — | US | claimed |
| CN-101679306-A | Heteroaryl amide substituted pyrimidone derivatives for the treatment of neurodegenerative diseases | SANOFI AVENTIS | 2010-03-24 | — | — | CN | claimed |
| EP-2162443-A2 | HETEROARYLAMIDE-SUBSTITUTED PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Sanofi-Aventis (FR) | 2010-03-17 | — | — | EP | claimed |
| US-20090306088-A1 | SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2009-12-10 | — | — | US | claimed |
| EP-2121635-A2 | SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES | Sanofi-Aventis (FR) | 2009-11-25 | — | — | EP | claimed |
| CN-101563328-A | Substituted heteroaryl pyridopyrimidinone derivatives | SANOFI AVENTIS (FR) | 2009-10-21 | — | — | CN | claimed |
| WO-2008155666-A2 | HETEROARYLAMIDE-SUBSTITUTED PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SANOFI-AVENTIS (FR) | 2008-12-24 | — | — | WO | claimed |
| EP-1992621-A1 | Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases | Sanofi-Aventis (FR) | 2008-11-19 | — | — | EP | claimed |
| WO-2008078196-A2 | SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-07-03 | — | — | WO | claimed |
| EP-1939187-A1 | Substituted heteroaryl pyridopyrimidone derivatives | Sanofi-Aventis (FR) | 2008-07-02 | — | — | EP | claimed |
| CN-112794860-B | Oxazole pyrimidone amide compound or medicinal salt thereof, preparation method and application | 上海肇钰医药科技有限公司 | 2021-06-29 | — | — | CN | disclosed |
| CN-112794860-A | Oxazole pyrimidone amide compound or medicinal salt thereof, preparation method and application | 上海肇钰医药科技有限公司 | 2021-05-14 | — | — | CN | disclosed |
| EP-1992621-A1 | Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases | Sanofi-Aventis (FR) | 2008-11-19 | — | — | EP | disclosed |
| WO-2008078196-A2 | SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-07-03 | — | — | WO | disclosed |
| EP-1939187-A1 | Substituted heteroaryl pyridopyrimidone derivatives | Sanofi-Aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306088-A1 | SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES | GSK3B, GSK3A, GSKIP | CTSA 2163/4885KDM4E 1739/4885ALOX15 2733/4885 |
| US-20100081677-A1 | HETEROARYLAMIDE PYRIMIDONE DERIVATIVES | DHFR, DPYD, HPRT1 | CTSA 2961/4885KDM4E 4133/4885ALOX15 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.